| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-05 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.22 | 2e-05 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | -0.17 | 6e-05 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.17 | 0.0001 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0002 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.18 | 0.0004 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0004 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.18 | 0.0006 |